Loading
Life sciences · Journal article
Molecular Diagnosis & Therapy · October 7, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Manganese-enhanced magnetic resonance imaging (MEMRI) is a functional imaging technique with several potential applications in various research fields. Manganese-enhanced magnetic resonance imaging uses paramagnetic manganese (II) ions (Mn 2+ ) as the contrast enhancer, as they accumulate mainly in the cytosol and mitochondria, shorten the longitudinal relaxation time (T₁) and thereby increase signal intensity on T₁-weighted sequences. Most often used in preclinical neuroimaging, MEMRI is also gaining attention in cancer research, providing potentially new insights into tumour biology and treatment response monitoring. The use of MEMRI faces challenges such as the potential toxicity of free manganese and the need for chelation (mangafodipir trisodium, MnPyC3A), careful dosing below ≈25 µmol Mn 2+ /kg and development of new imaging protocols. Ongoing translational research aims to improve the safety profile of manganese agents and optimise imaging strategies. Early clinical studies in neurology and cardiology are exploring MEMRI; clinical oncology use remains investigational and limited. We review preclinical advances and the limited early human experience, outlining safety considerations and the potential, yet unproven, effectiveness of MEMRI in oncology. The present review also contextualises MEMRI within the broader landscape of metal-based precision imaging and neutron capture therapy approaches, including boron neutron capture therapy and gadolinium neutron capture therapy, which represent complementary strategies exploiting the tumour-selective accumulation of specific metal ions. Recent clinical and translational evidence supports the maturation of these approaches: a phase II trial of accelerator-based boron neutron capture therapy with borofalan in head and neck cancer reported acceptable safety, and a systematic review across malignant tumours confirmed favourable efficacy and safety signals for boron neutron capture therapy. Manganese-based nanotheranostics are concurrently emerging as a route to combine magnetic resonance imaging with image-guided therapy.